ReoPro: Phase III European Capture trial

Centocor Inc. (CNTO), Malvern, Penn. Product: ReoPro, monoclonal antibody targeted at GP IIb/IIIa Indication: High-risk angioplasty Status: FDA inspected the Netherlands manufacturing facility in Jun...